All > Follicular Lymphoma > Revlimid

Acalabrutinib for Follicular Lymphoma

M D Anderson Cancer Center, Houston, TX
Follicular Lymphoma+6 More ConditionsAcalabrutinib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a combination of drugs to treat patients with a certain type of lymphoma. The drugs work in different ways to stop the growth of cancer cells.

Eligible Conditions
  • Follicular Lymphoma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

1
Radiation Therapy
1
Acalabrutinib
1
Acalabrutinib

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to 3 years

Year 1
Heart rate
Year 1
Complete remission rate
Year 3
Overall survival
Year 3
Progression-free survival
Year 3
Duration of response
Month 24
Progression-free survival within 24 months from treatment initiation
Up to 3 years
Alteration in immune cell subsets
Cell free circulating deoxyribonucleic acid (DNA)
Frequency of treatment-emergent AEs requiring study drug discontinuation or dose reduction
Frequency, severity, and relatedness of treatment-emergent adverse events (AEs)

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Radiation Therapy
1
Acalabrutinib
1
Acalabrutinib

Side Effects for

BSC Alone
2%Headache
1%Septic shock
1%Ischaemic stroke
1%Chronic obstructive pulmonary disease
This histogram enumerates side effects from a completed 2020 Phase 2 trial (NCT04346199) in the BSC Alone ARM group. Side effects include: Headache with 2%, Septic shock with 1%, Ischaemic stroke with 1%, Chronic obstructive pulmonary disease with 1%.

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

1 Treatment Group

Treatment (acalabrutinib, lenalidomide, rituximab)
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: Acalabrutinib · No Placebo Group · Phase 2

Treatment (acalabrutinib, lenalidomide, rituximab)Experimental Group · 3 Interventions: Rituximab, Acalabrutinib, Lenalidomide · Intervention Types: Biological, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved
Tyrosine
FDA approved
Lenalidomide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,843 Previous Clinical Trials
1,793,348 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,272 Previous Clinical Trials
41,230,735 Total Patients Enrolled
Paolo StratiPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
67 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 18 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

What is the government's stance on Acalabrutinib?

"Acalabrutinib's safety is based primarily on Phase 2 trial data, which means that while there is some evidence to support its safety, there is none for its efficacy." - Anonymous Online Contributor

Unverified Answer

What is the estimated amount of people who will be participating in this research project?

"That is correct, the online clinicaltrials.gov registry indicates that this research study is actively looking for participants. The trial was first advertised on 16/7/2020 and underwent its most recent update on 31/7/2022. In total, the investigators seek to enroll 24 individuals at a single medical facility." - Anonymous Online Contributor

Unverified Answer

Are applications for this research being accepted at the moment?

"Yes, this study is still recruiting patients. The listing on clinicaltrials.gov shows that the trial was posted on July 16th 2020 and updated as recently as July 31st, 2022." - Anonymous Online Contributor

Unverified Answer

What are some of the primary benefits of Acalabrutinib?

"Acalabrutinib is a medication used to treat chronic lymphocytic leukemia, but it can also help patients with diffuse large b-cell lymphoma (dlbcl) and kidney failure. If you have had two prior systemic chemotherapy regimens, this drug may be right for you." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top